Abbott Laboratories: Solid Performance in Key Sectors but Hold Rating Due to Mixed Outlook
Morgan Stanley analyst Patrick Wood maintained a Hold rating on Abbott Laboratories (ABT – Research Report) yesterday and set a price target of ...
Abbott Laboratories: Now Back In The Buy Zone (Rating Upgrade)
Abbott Laboratories just extended its dividend growth streak with a 7.3% hike in the quarterly dividend per share last month.
bovnews1d
Abbott’s (ABT) Impressive Q4 and Bold Projections for 2025: What You Need to Know
The company’s projected adjusted diluted EPS for 2025 is between $5.05 and $5.25, marking double-digit growth at the midpoint. Abbott’s first-quarter 2025 adjusted EPS is expected to be between $1.05 ...
Abbott Laboratories: Strong Performance and Promising Outlook Support Buy Rating
Analyst Lee Hambright of Bernstein maintained a Buy rating on Abbott Laboratories (ABT – Research Report), boosting the price target to ...
Abbott Q4 Earnings Meet, Margins Down, Stock Falls in Pre-Market
Abbott Laboratories ABT reported fourth-quarter 2024 adjusted earnings per share (EPS) of $1.34, in line with the Zacks ...
Abbott pushes toddler milks that can cause health issues: lawsuit
The lawsuit accuses the formula maker of deceptively marketing the milks to make them seem like the next recommended step for toddlers.
Abbott banks on glucose monitors, new launches to ride out China, currency hit
Abbott Laboratories on Wednesday forecast first-quarter profit below Wall Street estimates, along with weak fourth-quarter ...
Abbott Laboratories’ Growth Prospects and Market Leadership in MedTech Justify Buy Rating
BTIG analyst Marie Thibault maintained a Buy rating on Abbott Laboratories (ABT – Research Report) today and set a price target of ...